Skip to main content

6 Result(s)

within Lisa A. Damico-Beyer Remove this filter

and

  1. No Access

    Article

    Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration–effect relationship support clinical dose and regimen selection

    PRO95780, a human monoclonal antibody (mAb) against death receptor 5 (DR5/TRAIL-R2/TNFRSF10B), was developed for the treatment for cancer. Our objective was to characterize pharmacokinetics (PK) in mice, rats,...

    Hong **ang, Arthur E. Reyes II, Steve Eppler… in Cancer Chemotherapy and Pharmacology (2013)

  2. No Access

    Article

    Anti-Neuropilin-1 (MNRP1685A): Unexpected Pharmacokinetic Differences Across Species, from Preclinical Models to Humans

    To compare the pharmacokinetics (PK) of MNRP1685A, a human monoclonal antibody (mAb) against neuropilin-1 (NRP1), in mice, rats, monkeys, and cancer patients from a Phase I study to model with parallel linear ...

    Yan **n, Shuang Bai, Lisa A. Damico-Beyer, Denise **… in Pharmaceutical Research (2012)

  3. No Access

    Article

    Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model

    MNRP1685A (anti-NRP1) is a fully human IgG1 monoclonal antibody against neuropilin-1 (NRP1), a protein necessary for blood vessel maturation. MNRP1685A binds to free membrane-bound NRP1 (mNRP1) and circulating...

    Yan **n, Hong **ang, Denise **… in Journal of Pharmacokinetics and Pharmacody… (2012)

  4. No Access

    Article

    Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose

    MEHD7945A is a novel dual-action monoclonal antibody in which each of the two antigen-binding fragments is capable of binding to EGFR and HER3 with high affinity. It is being evaluated as a potential therapy f...

    Amrita V. Kamath, Dan Lu, Priyanka Gupta… in Cancer Chemotherapy and Pharmacology (2012)

  5. No Access

    Article

    Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma

    MFGR1877A is a human IgG1 monoclonal antibody that binds to fibroblast growth factor receptor 3 (FGFR3) and is being investigated as a potential therapy for relapsed/refractory FGFR3+ multiple myeloma. The pur...

    Amrita V. Kamath, Dan Lu, Priyanka Gupta… in Cancer Chemotherapy and Pharmacology (2012)

  6. No Access

    Article

    A Guide to Rational Dosing of Monoclonal Antibodies

    Dosing of therapeutic monoclonal antibodies (mAbs) is often based on body size, with the perception that body size-based dosing would reduce inter-subject variability in drug exposure. However, most mAbs are t...

    Dr Shuang Bai, Karin Jorga, Yan **n, Denise **, Yanan Zheng… in Clinical Pharmacokinetics (2012)